Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Septic Cardiomyopathy, Septic Shock
Conditions
Keywords
Extracorporeal Membrane Oxygenation, refractory septic shock, septic cardiomyopathy, cardiogenic shock
Brief summary
The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.
Detailed description
All patients who meet inclusion criteria and have no exclusion criteria are considered to be enrolled. During the period of study, the participants can decide whether to accept ECMO based on their personal conditions. If a patient is willing to accept ECMO treatment, we initiate VA-ECMO within 6 hours. Participants taking VA-ECMO during the period of study are referred to as cohort 1, and patients receiving only conventional therapy without ECMO belong to cohort 2. 30-day survival will be accessed to evaluate the survival benefit from ECMO therapy for sepsis-induced refractory cardiogenic shock.
Interventions
All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
Sponsors
Second Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 75 years. * Patients admitted into ICU and diagnosed as septic shock (sepsis-3.0)13, after adequate fluid resuscitation, high-dose vasoactive drug application \[vasoactive inotropic score (VIS) \> 120\] and conventional therapy together with at least one of the following criteria: (1) sustained hypotension \[mean arterial pressure (MAP) \< 65 mmHg\]; (2) persistent lactacemia (two consecutive values \> 5 mmol/L with at least 30 min interval between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors; (3) persistent low mixed venous blood oxygen saturation (SvO2) (two consecutive values \< 55% with at least 30 min interval between samples), with non-increasing trend on steady doses of inotropes and/or vasopressors. The above condition lasts more than 5 hours. * Rapidly deteriorating sepsis-induced myocardial impairment is defined by at least one of the following criteria: (1) rapidly deteriorating ventricular function (LVEF \< 35%); (2) cardiac index (CI) \< 2L/min/m2 (\> 3 hr); (3) emerging refractory arrhythmia. * Informed consent provided by the patient or person with decisional responsibility.
Exclusion criteria
* Cardiac dysfunction caused by other causes is excluded, such as acute myocardial infarction, chronic heart failure, congenital cardiac disease, myocardial effusion, moderate to severe aortic regurgitation, severe aortic coarctation and so on. * High suspicion of pulmonary embolism, tension pneumothorax or cardiac tamponade as a cause of shock. * Prolonged cardiac arrest (\> 30 min) before ECMO, or CPR survivors remaining comatose. * Irreversible condition or meet the inclusion criteria for more than 12 hr. * Presence of active bleeding or anticoagulant contraindications. * Peripheral artery disease disabling insertion of outflow cannula to femoral artery. * Irreversible neurological pathology * Severe underlying condition with lift expectancy less than 1 year. * Special population, such as pregnancy, acquired immune deficiency syndrome (AIDS). * Patient included in another interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day survival | From date of enrolled (D0) until date of death from any cause or day-30, whichever came first | survival rate at day-30 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| long-term survivors' cardiac function | at day-30 and 6-month | LVEF evaluated according to Doppler echocardiography |
| ICU survival rate | From date of enrolled (D0) until date of death from any cause or date of discharge from ICU, whichever came first, assessed up to 6 months | survival to ICU discharge |
| hospital survival | From date of enrolled (D0) until date of death from any cause or date of discharge from hospital, whichever came first, assessed up to 6 months | survival to hospital discharge |
| 6-month survival | From date of enrolled (D0) until the date of death from any cause or 6-month, whichever came first | survival rate at 6-month |
| successful rate of ECMO weaning | From date of weaning off ECMO until the date of death or 24 hours after ECMO weaning, whichever came first | Successful weaning is defined as maintaining stable condition within 24 hours of ECMO weaning. Analyzed the frequency of patients who weaning ECMO successfully |
| the number of days alive without CRRT, mechanical ventilation and vasopressor | between Day 0 and up to Day 30 | the numbers of CRRT-free days, mechanical ventilation-free days and vasopressor-free days |
| ICU length of stay (LOS) | From date of enrolled (D0) until the date of death from any cause or discharge from ICU, whichever came first, assessed up to 6 month | ICU LOS |
| hospital length of stay (LOS) | From date of enrolled (D0) until the date of death from any cause or discharge from hospital, whichever came first, assessed up to 6 month | hospital LOS |
| quality of life for long-term survival | at 6-months | evaluate through EuroQol Five Dimensions Questionnaire Descriptive System at 6-month within survivors, the minimum value is 3, the maximum value is 15, higher scores mean a worse state. |
Other
| Measure | Time frame | Description |
|---|---|---|
| safety assessments | from the date of enrolled (D0) until death or day-30, whichever came first. | the rate of complications potentially related to ECMO treatment, including major bleeding associated with anticoagulants, thrombosis, leg ischemia and cannulation-related injuries. |
Countries
China
Contacts
Primary ContactWei-yan Chen
Backup ContactDe-liang Wen
Outcome results
None listed